http://bulrad.bg/?page_id=91399mTc-MIBI scintigraphy, bone scintigraphy and beta-2-microglobulin for diagnosis and therapy control in patients with multiple myeloma
|D. Vassileva, A.Tzonevska|
Bone marrow involvement as well as the bone destruction, is a characteristic and usual feature of myeloma. The aim of the study was to assess the possibility of radionuclide imaging with 99mTc-MIBI and 99mTc-MDP for detecting bone marrow infiltration and skeletal lesions and the serum beta-2-microglobulin in diagnosis, staging and therapy control of in myeloma patients. Scintigraphic imaging in 82 patients with myeloma were carried out 30 min and 3 hours after i.v. injection of 740 MBq 99mTc-MIBI and 3 hours after intravenous injection of 740 MBq 99mTc-MDP. Serum beta-2-microglobulin levels were measured by radioimmunoassay.In patients with negative bone scintigraphy, the positive 99mTc-MIBI scan defined bone marrow involvement before other imaging methodsIn patients with bone lesions both 99mTc-MIBI and 99mTc-MDP scintigraphy were true positive. The scans detected lesions especially in the femur, humerus, ribs, sternum, thoracic and lumbar spine, pelvis. Positive bone scintigraphy with 99mTc-MDP were detected in convalescent period in patients after pathologicalfractures and after therapy in relation to periostal reactionand the reactive bone formation. The 99mTc-MIBI scans inthese patients were negative. No abnormal images on both scintigraphies were foundin patients, defined as a disease remission.The results showed the possibility of the 99mTc-MIBI and 99mTc-MDP scintigraphy in different stages of the disease and the necessity of complete investigation for diagnosis, staging and therapy control in myeloma patients. The scintigraphy data schowed a good correlation with the level of serum beta-2-microglobulin.
Key words: MULTIPLE MYELOMA. 99mTc-MIBI AND 99mTc-MDP SCINTIGRAPHY. SERUM BETA-2-MICROGLOBULIN. DIAGNOSIS AND THERAPY CONTROL